Based on real-world data from 24 laryngeal cancer patients treated at the Gansu Wuhui Heavy Ion Center, this study summarizes the efficacy of heavy (carbon) ion therapy in early-stage, advanced-stage, and recurrent laryngeal cancer. The data indicate that survival rates are comparable to international standards and significantly superior to traditional therapies. This approach is particularly suitable for patients requiring voice preservation or those ineligible for surgery, offering a new choice for precise, low-toxicity curative treatment.

Prostatic sarcoma is an extremely rare but highly malignant tumor of the prostate that originates from mesenchymal tissues (such as muscle and vascular connective tissue), distinguishing it fundamentally from common prostate cancer, which arises from glandular epithelial cells.

From Marie Curie's discovery of radium, which opened the century-long exploration of nuclear medicine, to today's precise radiopharmaceuticals becoming a core weapon in combating advanced tumors, nuclear medical technology has continuously evolved, lighting up hope for survival for patients with difficult-to-treat cancers. Recently, the Department of Nuclear Medicine at Wuwei Tumor Hospital in Gansu Province is about to complete all necessary approval procedures, becoming the first medical institution in Gansu Province and a leading facility in Northwest China with clinical application qualifications for radium-223 (²²³Ra). This enables routine α-particle targeted radionuclide therapy for bone metastases in castration-resistant prostate cancer, filling a technological gap in the Northwest region and marking a new milestone in the comprehensive precision diagnosis and treatment capabilities of our hospital's nuclear medicine department.

The Wuwei Heavy Ion Center is equipped with China's first heavy ion therapy system with fully independent intellectual property rights. Since the first patient received carbon ion therapy in November 2018, as of March 15, 2026, over 2,800 patients have been treated for more than 100 types of diseases. Among them, 15 cases of gastric cancer were treated, and this summary is hereby presented.

Gansu Province Wuwei Tumor Hospital has been approved for its first provincial chief scientist project, led by Professor Ye Yancheng to tackle radiation-resistant tumors with carbon ion therapy. Leveraging 30 major research platforms and 9 globally advanced technologies, the hospital is developing a "China Solution" to provide new hope for precise treatment of refractory cancers such as pancreatic cancer and glioblastoma.

Cholangiocarcinoma, often dubbed the "silent killer" due to its insidious onset, rapid progression, and limited treatment options, is now being addressed in Wuwei, Gansu, where a cutting-edge technology hailed as a "national treasure"—heavy ion (carbon ion) therapy—is forging a new lifeline for patients with robust clinical data.

Gansu's first sub-center of the National Clinical Research Center for Digestive Diseases has been established at Wuwei Tumor Hospital. Academician Fan Daiming and other experts joined forces to promote the application of new strategies for risk stratification and sequential screening of upper gastrointestinal cancers, inaugurating a new chapter in the integrated prevention, screening, diagnosis, treatment, and rehabilitation of digestive tumors along the Hexi Corridor.

Carbon ion therapy has demonstrated unique advantages and reliable efficacy for tracheal tumors—whether primary squamous cell carcinoma or adenoid cystic carcinoma of the trachea, or secondary tracheal invasion from other malignancies. The following summarizes our center's recent treatment experiences and data for reference by colleagues and patients alike.